A Study Examining the Medication Apremilast as Treatment for Chronic Itch

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Washington University School of Medicine
Study ID
NCT03239106
Phase
PHASE2
Status
Completed

Conditions

  • Itch

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Chronic Itch is a debilitating condition affecting many people. Currently, there are no FDA-approved treatments. Apremilast is an FDA-approved oral medication used to successfully treat the inflammatory skin disorder psoriasis and the inflammatory disorder psoriatic arthritis. This study examines if apremiliast taken twice daily relieves chronic itch.

Key Dates

First listed
Aug 3, 2017
Start date
Dec 1, 2017
Status verified
Jun 2021
Primary completion
Oct 31, 2018
Completion
Sep 19, 2019

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: open label
    All participants will receive Apremilast 30 mg BID.

Primary Outcome Measure

Absolute NRS Itch Score at Week 16 (End of Treatment) [ Time Frame: Week 16 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Washington University Division of DermatologySt LouisMissouri63108-

Find similar trials in St Louis, MO

By research site
Washington University Division of Dermatology· St Louis, MO

Related Studies